Entering text into the input field will update the search result below

Nektar Therapeutics' (NKTR) CEO Howard Robin on Q4 2017 Results - Earnings Call Transcript

Mar. 01, 2018 11:40 PM ETNektar Therapeutics (NKTR)
SA Transcripts profile picture
SA Transcripts

Nektar Therapeutics (NASDAQ:NKTR) Q4 2017 Earnings Conference Call March 1, 2018 5:00 PM ET


Howard Robin - President, Chief Executive Officer

Gil Labrucherie - Chief Financial Officer

Dr. Steve Doberstein - Chief R&D Officer

Dr. Jonathan Zalevsky - Chief Scientific Officer

Mary Tagliaferri - Chief Medical Officer

Jennifer Ruddock - Senior Vice President, Investor Relations


Chris Shibutani - Cowen

Jessica Fye - JPMorgan

Bert Hazlett - BTIG

Difei Yang - Mizuho Securities

Andy Hsieh - William Blair

David Steinberg - Jefferies


Good day ladies and gentlemen, and welcome to the Nektar Therapeutics Q4 and Year End 2017 Financial Results Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call may be recorded.

I would now like to introduce your host for today's conference, Ms. Jennifer Ruddock, Senior Vice President, Investor Relations. Please go ahead.

Jennifer Ruddock

Thank you, Crystal. Good afternoon and thank you for joining us today. With us are Howard Robin, our President and CEO; Gil Labrucherie, our Chief Financial Officer; Dr. Steve Doberstein, our Chief R&D Officer; Dr. Jonathan Zalevsky our Chief Scientific Officer and Mary Tagliaferri our Chief Medical Officer. Several members of our team are joining from different locations. So we ask for your patience today during Q&A, if there is any lag in our response time.

On this call we expect to make forward-looking statements regarding our business, including the timing of future clinical trials and clinical trial results, clinical development plans, the economic potential of our collaboration partnerships, the therapeutic potential of certain drugs and drug candidates, as well as those of our partners, our financial guidance for 2018 and certain other statements regarding the future of our business.

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.